A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Dose Escalating Study To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-03864086 In Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2008
At a glance
- Drugs PF 3864086 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- 15 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2008 Planned end date changed from 1 Nov 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.
- 18 Nov 2008 Planned number of patients changed from 20 to 28 as reported by ClinicalTrials.gov.